Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

End of the Year Decisions ~ Part 4

March 14, 2019 0

Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio …

Atossa Genetics’ news that staged a huge Rally of this small firm’s stock

March 14, 2019 0

Atossa Genetics (ATOS) announced that the FDA has issued a “Safe to Proceed” letter under their “expanded …

Gene therapy: Speeding down the road towards offering cures. A small firm might have some good news

March 12, 2019 0

We love to read news about gene therapy as it is the only possibility for curing …

Exelixis moves more products into clinical trials. Alnylam’s product Givosiran demonstrates efficacy in Acute Hepatic Porphyria (AHP). Why investors have caused a stock selloff.

March 6, 2019 0

Thanks to abundant cabozantinib sales’ revenues Exelixis (EXEL) is advancing a new generation of its medicines …

Good news and setbacks during the departed week

March 5, 2019 0

The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the …

Why CRISPR Therapeutics’ stock gained around $8 today

February 25, 2019 0

CRISPR Therapeutics' (CRSP) stock added around $8 today while reporting financial results for the fourth quarter …

Spark Therapeutics to be acquired by Roche at $113.47 UP $61.91

February 25, 2019 0

We congratulate our subscribers who kept Spark Therapeutics (ONCE) in spite of the stock’s kind of paralysis for no …

Cytokinetics’ heart failure drug omecamtiv mecarbil advancing into late phase trials

February 23, 2019 0

Cytokinetics’ (CYTK) investigational product omecamtiv mecarbil, the firm’s potential treatment for heart failure with reduced ejection fraction, …

Merck’s product Keytruda and Exelixis’ product Cabometyx are both winners

February 21, 2019 0

Keytruda and Cabometyx Are Both Winners Keytruda failed to meet co-primary endpoints in Pivotal Phase 3 …

The Week in Review #37

February 19, 2019 0

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …

Nektar presentation today at the ASCO genitourinary cancers symposium

February 15, 2019 0

Today, at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU) held at …

RegenxBio: An analyst and investor event focused on the firm’s ophthalmology program.

February 15, 2019 0

RegenxBio (RGNX), a clinical-stage gene therapy firm with a proprietary NAV® Technology Platform, will host an analyst and investor …

Exelixis’ excellent scientific and financial accomplishments

February 13, 2019 0

Exelixis’ (EXEL) financial results for the fourth quarter and full year 2018 are as inspiring as they are …

Portola: On the right track

February 12, 2019 0

Portola Pharmaceuticals (PTLA) announced full results from ANNEXA-4, Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® in …

Successful results were announced by uniQure for its gene therapy, AMT-061, on hemophilia B patients

February 11, 2019 0

The United States FDA granted Breakthrough Therapy Designation to AMT-061. The European Medicines Agency gave it …

End of the Year Decisions ~ Part 3

February 10, 2019 0

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …

ImmunoGen’s Report and Standing. Why Biogen Is Experiencing a Selloff

February 8, 2019 0

ImmunoGen & Biogen News About ImmunoGen ImmunoGen (IMGN) is a creator and developer of antibody-drug conjugates (ADCs) …

Halozyme signs another license agreement this time with argenx

February 5, 2019 0

Halozyme Therapeutics (HALO) and argenx (ARGX) announced a global collaboration and license agreement offering argenx the right to use …

RegenxBio product RGX-181 has been granted FDA Rare Pediatric Disease Designation for Batten Disease Condition known as CLN2

February 1, 2019 0

FDA Granted Rare Pediatric Disease Designation for RegenxBio’s Product RGX-181 for CLN2 RegenxBio RegenxBio (RGNX), a …

Merck’s superior accomplishments